 Spectrum --
August 2008
 Introduction:
The initial public offering (IPO) market for biotech and
specialty pharma companies has been nearly lifeless in 2008. Investment bankers
are unimpressed by the performance of these companies, and money managers are
reluctant to support a negative trend. The other side of intense pessimism,
however, is that money accumulates on the sidelines where life science
investors ultimately become impatient with money market returns and look for
places to put risk capital to work. We demystify the best way to navigate the
startup route through three in-depth Spectrum Expert Commentaries. A
fresh and comprehensive look at IPOs and industry trends demonstrates that the
future is not all bleak.
Get the Answers You Need to Shape Your Strategy:
 Having raised enough money, filed the sufficient forms, and
ensured your leading compound is in the intended phase of development are all
important factors in the decisions companies make before going public. What
steps, when implemented, will further the likelihood of a successful IPO
filing? How can competitors’ strategies be interpreted based on their
decisions?
Despite the unstable state of today’s economy, not every
startup is aiming to be acquired by a larger firm. What exit strategies are
particularly common among those biotech startups that are performing well? What
motivates the investors that are observing from the sidelines?
Expert opinion is unanimous: establishing a strong game plan
early in the process of the pathway to going public—and sticking to it—is
essential. How can a biopharma or diagnostics company looking to
invest in a startup influence that process to create a win-win for all parties
involved?
Scope:
Overview of the biotechnology startup landscape: market
overview, market performance, 2007-2008 IPOs, status of startups’ lead
compounds in development.
Company profiles: detailed company profiles of
six startups that are making strides in today’s tough economy—Molecular Insight
Pharmaceuticals, NeurogesX, NovaBay Pharmaceuticals, Optimer Pharmaceuticals,
Orexigen Therapeutics, and Rosetta Genomics.
Spectrum Expert Commentaries: in-depth analysis
from innovative, accomplished, and renowned scientist entrepreneurs who provide
valuable strategic insight and advice to early-stage companies.
Specific insight for young companies: advice on how to
plan for the IPO road show; issues to consider regarding investor relations;
and the advantages of a strong management team.
|
